According to antibody analysis, approximately two of every three intravenous drug users in Iceland have become infected with hepatitis C virus (HCV). In this study, serum samples from 55 HCV antibody-positive intravenous drug users (39 males and 16 females) were analyzed by polymerase chain reaction, and the viral strains were grouped into genotypes. Only three genotypes-1 a, 3a, and 1 b-were found among the drug users. Of 40 persons who were positive by polymerase chain reaction, 23 (57.5%) had type 1a, 15 (37.5%) had type 3a, and one (2.5%) had type 1b. One serum sample was untypeable. HCV viral RNA was detectable in 84.6% of the males and 43.7% of the females, which is a significant difference between the sexes (p < 0.01). In addition, 41 randomly selected HCV antibody-positive intravenous drug users (17 males and 24 females) were tested for HCV viral RNA with a commercially available polymerase chain reaction technique. In this subset of drug users, 76.4% of the males and 33.3% of the females had detectable HCV RNA in their serum, which is also a significant sex difference (p < 0.01). This study shows that two HCV genotypes predominate among intravenous drug users in Iceland, and the results indicate that women eliminate virus more effectively than men. Am J Epidemiol 1996; 143:631-6. genotype; hepatitis C viruses; sex factors; substance abuse, intravenous; viremia
The recently identified hepatitis C virus (HCV) causes most cases of the parenterally transmitted hepatitis virus infection previously designated non-A, non-B (1) (2) (3) (4) . A large proportion of infected individuals become chronic carriers of the virus and may develop serious long term sequelae (5-7). The natural mode of transmission is not clear, but frequently the virus is transmitted among intravenous drug users who share syringes (8) . Prior to routine screening for HCV antibodies at blood banks, HCV was commonly transmitted by blood transfusions or clotting factors (3) .
In Iceland, intravenous drug use is a relatively recent health problem. It seems to have been introduced into the country in the early 1980s with an onset of intravenous amphetamine use (T. Tyrfingsson, Vogur Hospital (Reykjavik, Iceland), personal communication, 1993). HCV infection among intravenous drug users was first detected retrospectively in a serum sample from 1984. Since then, the prevalence of HCV antibodies among intravenous drug users seeking medical care has increased steadily, and it has reached 60-70 percent in recent years (9) .
By utilizing type-specific primers to the putative nucleocapsid (core) gene, it is possible to use the polymerase chain reaction (PCR) method to define several genotypes of HCV. On this basis, Okamoto et al. (10, 11) described four genotypes, I-IV, and later genotype V (3a). Simultaneously, Chan et al. (12) , by utilizing other parts of the HCV genome, described genotypes designated la, lb, 2a, 2b, and 3, which correspond to Okamoto et al.'s genotypes I-V, respectively. The classification of hepatitis C genotypes is still undergoing revision and improvement (13) .
In this study, 55 HCV-seropositive intravenous drug users living in Iceland were analyzed for HCV RNA in serum using a previously described method (14) . Genotyping was done by PCR, utilizing type-specific primers to assess the frequency of each genotype (13) . In addition, the frequency of HCV viremia was investigated in 41 additional intravenous drug users of both sexes using a commercially available HCV PCR assay. 
MATERIALS AND METHODS
Blood samples were obtained from the drug users after they had visited physicians for various reasons, such as detoxification, infection, jaundice, and psychiatric problems. The blood samples were collected during the years 1991-1993 and were sent to either of two virus laboratories for processing: the Department of Medical Virology at the University of Iceland or the Microbiological Laboratory at City Hospital in Reykjavik. For HCV antibody determination at the Department of Medical Virology, the second generation Ortho enzyme-linked immunosorbent assay (ELISA) was employed, and confirmation was performed with the second or third generation Ortho recombinant immunoblot assay (RIBA) (Chiron Corporation, Emeryville, California). At the Microbiological Laboratory at City Hospital, the second generation Abbott ELISA (Abbott Laboratories, Abbott Park, Illinois) was used, and confirmation was made with the second generation RIBA.
Two sets of drug users were tested. The first set (group I) consisted of 55 users (39 males and 16 females), and the second set (group II) consisted of 41 users (17 males and 24 females).
Group I was analyzed as follows. The PCR for typing and diagnosis of HCV was performed according to previously described methods utilizing a moderately conserved segment of the putative core gene for typing (10, 13) and a conserved segment of the 5' end noncoding region for confirmation of HCV diagnosis (14) .
The viral RNA was extracted from 100 fx\ of serum with the acid guanidinium thiocyanate-phenol-chloroform method of Chomczynski and Sacci (15) as modified by Widell et al. (13, 14) . Between analyses of all serum samples, water controls were included to detect possible contamination, and a weak positive control was included among every six serum samples.
The typing PCR method utilized a segment of the putative HCV nucleocapsid (core) gene (13) . The first typing step involved combined reverse transcription and the initial outer PCR to amplify a 284-base-pair segment of the core gene. After mixing of the extracted viral RNA with the PCR reagent mix, reverse transcription was performed at 43°C for 60 minutes. Subsequently, thermocycling in a Perkin-Elmer (Perkin-Elmer Corporation, Norwalk, Connecticut) or Hybaid (Hybaid, Teddington, England) thermocycler was carried out for 35 cycles as follows: melting at 94°C for 1.5 minutes, annealing at 50°C for 2 minutes, and elongation at 72°C for 3 minutes.
The second inner typing PCR was divided into two parts. The typing primer for type la was 5'-TGGG-GATAGGCTGACGTCTACCT (antisense); for type lb, it was 5'-CCATCCTGCCCACCCCA (antisense); for type 2a, it was 5'-CCAAGAGGGACGGGAAC-CTC (antisense); and for type 2b, it was 5'-GCAAC-CCTCGTTTCC(GA)TACAGAG (antisense). These primers were run against a sense upstream primer, 5'-AGGAAGACTTCCGAGCGGTC. Type 3a was identified with primer 5'-GTGTGCGCGACGCG-TAAA (sense) and a consensus primer, 5'-GCA(TC)GT(AG)AGGGTATCGATGAC(TC)T (antisense); in this reaction, type lb was also confirmed with primer 5'-AACCTCGTGGAAGGCGACAA (sense). The second typing PCR was done under stringent conditions, consisting of 25 cycles in a PerkinElmer thermocycler as follows: melting at 94°C for 1 minute, annealing at 63°C for 1 minute, and elongation at 72°C for 1.5 minutes. Lastly, the final amplification product was mixed with bromophenol blue, electrophoresed on an agarose gel, visualized, and photographed after staining with ethidium bromide as previously described (14) .
Samples that were negative according to the typing PCR were reanalyzed with a diagnostic nested PCR, utilizing primers directed to the conserved 5' end noncoding region of the viral genome. The sequence of the outer primers was 5'-CATGGTGCACGGTC-TACGAGACC-3' (antisense) and 5'-GGCGA-CACTCCACCATAGATC-3' (sense). The sequence of the inner primers was 5'-TCGCAAGCACCCTAT-CAGGCAG-3' (antisense) and 5'-GGAACTACT-GTCTTCACGCAGA-3' (sense) (14) . The viral RNA was reextracted from fresh serum, and the procedure was performed as previously described (14) . The sensitivity of this assay was approximately 3-10 50 percent infectious doses in chimpanzees per milliliter of strain H HCV (obtained from a patient with acute HCV infection) (14) .
Group II consisted of 41 randomly selected HCV antibody-positive intravenous drug users whose viral RNA was analyzed by the HCV PCR Amplicor test (Roche Diagnostic Systems, Mississanga, Ontario, Canada). The test was performed according to the manufacturer's instructions. The sensitivity of the Amplicor assay is approximately one third lower than that of the aforementioned in-house test (A. Widell, unpublished evaluation of the Roche Amplicor HCV test, 1994).
Statistical analysis was carried out with the Yates corrected chi-square test (16) and Fisher's exact test.
(aspartate aminotransferase and/or alanine aminotransferase)) for the 55 intravenous drug users are shown in table 1. Genotypes la and 3a were the most common genotypes found. Only one exception, type lb, was found among the 55 drug users. Thus, of 40 PCRpositive individuals, 23 had type la (57.5 percent), 15 had type 3a (37.5 percent), and one had type lb (2.5 percent); one sample was untypeable. In 15 of the 55 drug users (27.3 percent), no HCV RNA could be detected, either by typing or by diagnostic PCR. Overall, 72.7 percent of the HCV antibody-positive drug users were positive by PCR; among the 39 males, 33 (84.6 percent) were positive by PCR, in contrast to the 16 females, of whom seven (43.7 percent) were positive by PCR. This difference was highly significant (p < 0.01).
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HCV PCR-positive individuals had elevated liver enzyme levels and only four had normal enzyme levels. In contrast, only two of 11 persons in the HCV PCRnegative group had definitely elevated levels of liver enzymes and one had marginally elevated levels, compared with eight who had normal enzyme levels (p < 0.01).
Group II
For further verification of the sex difference in the findings, 41 additional intravenous drug users were studied. Thirteen of 17 males (76.4 percent) but only eight of 24 females (33.3 percent) were found to be positive for viral RNA by the Amplicor PCR technique. This is also a significant difference (p < 0.01), and it is in agreement with the previous results obtained using the in-house PCR tests on study group I.
The prevalence of viremia by age and sex in the 96 HCV antibody-positive individuals (groups I and II) is shown in table 2. The table demonstrates that most of the intravenous drug users were between 20 and 40 years of age, and it highlights the large number of HCV antibody-positive but HCV PCR-negative female drug users aged 20-29 years.
DISCUSSION
Genotyping of HCV can be useful in several situations, such as the monitoring of nosocomial infections in hemodialysis units (13) . Medicolegal questions concerning tracing of HCV infection can also potentially be clarified by genotyping.
The various HCV genotypes seem to have a certain geographic distribution, although the divisions are not clear. Type la is most prevalent in Western Europe and the United States, type lb in Germany and Asia, types 2a and 2b in Asia, and type 3 a in northwestern Europe (17, 18) . Among HCV-infected blood donors in Sweden, 57 percent had type la, 19 percent had type 3a, 13 percent had type lb, and 11 percent had type 2b, while type 2a was not found (13) .
The present study demonstrates that two genotypes of HCV, la and 3a, predominate among HCV-infected intravenous drug users in Iceland. The only drug user infected with genotype lb was of foreign origin, though of Nordic ethnicity. Icelandic intravenous drug users have social contact mostly with persons in the major cities of Northern Europe, where both of these genotypes, la and 3a, are common (13) . In many other areas, e.g., Europe and the United States, a more diverse pattern of genotypes is found (13, 18) . In Scotland, which is close to Iceland, it has been reported that the predominant genotypes are la and 3a (12) . The fact that only two genotypes predominate among intravenous drug users in Iceland might suggest that most of these users were infected by a few individuals who originally carried HCV into the country. Iceland has a small population of 260,000, half of whom live in the capital city area. HCV seems to have spread within the growing intravenous drug user population that emerged in the early 1980s. Similar introduction of other new bloodborne viruses has been documented among intravenous drug users-e.g., hepatitis D in a Swedish urban population in the mid1970s (19) and, more recently, the various retroviruses (20) (21) (22) .
Hepatitis B virus, which leads to a chronic carrier state only in a few percent of infected adult individuals, has been observed to cause short-lived epidemics among intravenous drug users (23, 24) . In contrast, this study supports previous ones (13, 25) in demonstrating that a high percentage of HCV antibody-positive individuals are viremic by the PCR technique, which leads to more long-standing and effective spread of the virus among intravenous drug users, who frequently share needles. It is evident that a certain percentage of HCV-infected antibody-positive individuals are able to eliminate the virus (13, 25) . It should be emphasized that the presently used diagnostic HCV PCR test has been demonstrated to have approximately one third more sensitivity than the commercially available Roche Amplicor HCV PCR test (A. Widell, unpublished evaluation of the Roche Amplicor HCV test, 1994). Where liver enzyme data were available, it is evident that most HCV antibody-positive but PCR-negative individuals had normal liver enzyme levels. This corroborates previous observations of HCV-infected blood donors, where neither elevated liver enzyme levels nor liver damage was observed in HCV antibody-positive, PCR-negative individuals (25) . Normalization of liver enzyme levels, however, does not always indicate clearance of HCV viremia (26) . In this study, elevated liver enzyme levels among HCV antibody-positive but PCR-negative intravenous drug users may have been due to use of liver-toxic substances.
It is noticeable that in spite of presumably repeated exposure to HCV, infected individuals seem to harbor only one viral genotype. This has also been observed in a blood donor-recipient study that used the same typing assay as this study (27) . Blood recipients had received blood or blood products from HCV-infected donors who later were found to be intravenous drug users. The same three genotypes were found among the blood donors as were found in the present studyi.e., mostly types la and 3a but also type lb-and all recipients had the same genotype as the donor and that type only (except one who, over a period of several years, had received multiple plasma transfusions from donors of unknown HCV status). It seems that either the first infecting genotype prevents the establishment of other genotypes or, alternatively, the most replication-competent genotype supersedes earlier ones, leading to one genotype in the infected individual. Although this PCR technique with competing typespecific primers is able to detect each of the HCV genotypes, including 2a and 2b (which were not found in this study), it is possible that the method would not detect some virus populations of low quantity.
Significantly fewer females than males had detectable viral RNA in serum by both PCR methods, indicating that females may eliminate the virus more effectively than males. The possible mechanism for this is unknown. The exact duration of HCV infection in each drug user could not be accurately determined in this study. HCV antibody-positive, PCR-negative females were generally very active drug users, many of them starting at a young age. Consequently, longstanding infection is not likely to be a crucial factor in elimination of the virus. Corroborating this is a recent study in which some HCV-infected individuals cleared the virus in only a few weeks (26) . Similarly, because of the very active drug abuse, it is unlikely that low viral challenge doses play a role in HCV elimination, especially in young females. A more efficient response with protective antibodies has been noted for females than for males among persons vaccinated against hepatitis B and hepatitis A (28, 29) . When the intensities of the RIBA bands between males and females were compared in this study, no sex difference was observed. However, the antibodies detected by the diagnostic RIBA are not thought to be neutralizing. If future studies confirm this presently observed sex difference in eliminating HCV, elucidating the mechanism responsible should be a priority, since this may have therapeutic value in the treatment of HCV infection.
